Details:
Large routine clinical practice study, ETNA-AF-Europe, demonstrates continued benefits of edoxaban across age groups and supports treatment in elderly patient populations, in line with those observed in ETNA-AF after one year and in ENGAGE AF-TIMI 48.
Lead Product(s): Edoxaban Tosylate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lixiana
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2021